Soin Therapeutics Inc.

Soin Therapeutics Inc.Soin Therapeutics Inc.Soin Therapeutics Inc.

Soin Therapeutics Inc.

Soin Therapeutics Inc.Soin Therapeutics Inc.Soin Therapeutics Inc.
More

Developing a novel formulation of low dose naltrexone to treat CRPS

Developing a novel formulation of low dose naltrexone to treat CRPSDeveloping a novel formulation of low dose naltrexone to treat CRPSDeveloping a novel formulation of low dose naltrexone to treat CRPS

Developing a novel formulation of low dose naltrexone to treat CRPS

Developing a novel formulation of low dose naltrexone to treat CRPSDeveloping a novel formulation of low dose naltrexone to treat CRPSDeveloping a novel formulation of low dose naltrexone to treat CRPS

About Us

Who We Are

Soin Therapeutics is a  pharmaceutical company that is developing new medications to treat rare, orphan diseases. Our lead product is a novel formulation of naltrexone for patients who suffer from complex regional pain syndrome (CRPS). It has received orphan drug status from the FDA. CRPS is a painful, debilitating disease and we believe we  found a solution that can be helpful to many people who are suffering.

About CRPS

Complex Regional Pain Syndrome is a rare, orphan disease characterized by severe pain, usually starting in an extremity, and associated with extreme swelling, limited range of motion, changes to the skin or bone structure, and debilitating pain

What We Are Doing

At Soin Therapeutics our ultimate goal is to get a high quality and effective formulation of low dose naltrexone on the market. We have developed a new oral pill that we believe has several advantages to help suffering patients. Our current formulation still requires FDA approval.

Articles and Clinical Data

Systematic Review Done by Soin Therapeutics

Systematic Review Done by Soin Therapeutics

Systematic Review Done by Soin Therapeutics

Published in a major medical journal, this review article written by the Soin Team highlights the clinical data on the use of LDN to treat CRPS.

Learn more

Published Case Report

Systematic Review Done by Soin Therapeutics

Systematic Review Done by Soin Therapeutics

Published in the journal Pain Medicine Case Reports, this article written by the Soin Team is a case report of the use of LDN to treat CRPS.

Learn more

Orphan Drug Designation

Systematic Review Done by Soin Therapeutics

Orphan Drug Designation

Soin Therapeutics was granted an Orphan Drug Designation by the FDA to treat CRPS with LDN


Learn more

Background

Our Founder

Dr. Amol Soin is a quadruple board certified pain management physician who saw the suffering of patients with CRPS and decided to do something about it. Dr. Soin has invented multiple medications and medical devices to treat pain without addiction. He has founded numerous biotech companies, holds several patents, his research has been published extensively in multiple medical journals, and has served as president of the Ohio Medical Board, president of the American Society of Interventional Pain Physicians, president of the Society of Interventional Pain Management Surgery Centers, as well as several other organizations. He is also a professor at three different medical schools, and runs his own pain management research laboratory.  Additionally, Dr. Soin has 5 college degrees including two from Ivy League Schools: Dartmouth and Brown. 

What is LDN?

Low Dose Naltrexone, LDN, is a medication that is used to treat addiction. However, recent evidence suggests that at low doses (5mg or less) it has very unique effects at treating pain and the disease cascade associated with complex regional pain syndrome (CRPS).

How Dose It Work?

LDN  acts on a receptor in the body known as TLR (Toll Like receptor) and through this, has been shown to reduce pain. Additionally, it is thought to increase your body's endorphins, which are natural pain killers.  It is also thought to decrease the activity of cells called microglial cells which are responsible for pain, as well as  decrease the activity of interleukins which are involved in nerve inflammation. The drug seems uniquely suited to treat the disease process in CRPS.

 

 

 

Our Research Has Been featured in several news stories

Formulation Complete

Podcast Featured on Entreprenuer.com

Formulation Complete

Soin Therapeutics Completes Formulation Work on Novel Pill to Treat CRPS

Learn more

LDN to Treat CRPS

Podcast Featured on Entreprenuer.com

Formulation Complete

Soin Therapeutics was featured in an article on the use of LDN to treat CRPS

Learn more

Orphan Drug Status

Podcast Featured on Entreprenuer.com

Podcast Featured on Entreprenuer.com

Soin Therapeutics obtained Orphan Drug Status from the FDA on their lead LDN drug

Learn more

Podcast Featured on Entreprenuer.com

Podcast Featured on Entreprenuer.com

Podcast Featured on Entreprenuer.com

Amol Soin was featured on a podcast for Entrepreneur Magazine discussing LDN 

Learn more

Contact Us

Drop us a line!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Send us a message if you'd like to learn more....

Currently LDN for CRPS is NOT FDA approved. We plan to complete rigorous human trials to prove safety and efficacy for our novel formulation. Then we can finally help patients who are suffering from CRPS. We look forward to advancing the science and for a brighter tomorrow for our patients.

Soin Therapeutics

Hours

Mon

09:00 am – 05:00 pm

Tue

09:00 am – 05:00 pm

Wed

09:00 am – 05:00 pm

Thu

09:00 am – 05:00 pm

Fri

09:00 am – 05:00 pm

Sat

Closed

Sun

Closed

Copyright © 2022 Soin Therapeutics - All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept